1. Show article details.

    PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

    Business Wire – 4:05 PM ET 04/07/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:00am ET.

  2. Show article details.

    BRIEF-Avidity Partners Management Reports 9.4% Passive Stake In Phasebio Pharmaceuticals

    Reuters – 5:43 PM ET 03/22/2021

    Avidity Partners Management: * AVIDITY PARTNERS MANAGEMENT LP REPORTS 9.4% PASSIVE STAKE IN PHASEBIO PHARMACEUTICALS INC AS OF MARCH 18 - SEC FILING Source: Further company coverage:

  3. Show article details.

    PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Business Wire – 4:05 PM ET 03/22/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the closing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $3.50 per share, including the full exercise of the underwriters’ option to purchase an ad...

  4. Show article details.

    BRIEF-PhaseBio Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

    Reuters – 10:13 PM ET 03/17/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 16,000,000 SHARES OF COMMON STOCK AT PRICE OF $3.50 PER SHARE Source text for Eikon: Further company coverage:

  5. Show article details.

    PhaseBio Announces Pricing of Public Offering of Common Stock

    Business Wire – 10:10 PM ET 03/17/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $3.50 per share.

  6. Show article details.

    BRIEF-Phasebio Pharmaceuticals Says Commenced An Underwritten Public Offering Of Shares Of Common Stock

    Reuters – 5:15 PM ET 03/17/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. * PhaseBio Pharmaceuticals Inc (PHAS) - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

  7. Show article details.

    PhaseBio Announces Proposed Public Offering of Common Stock

    Business Wire – 5:02 PM ET 03/17/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. Cowen, Stifel and William Blair are acting as joint book-running managers for the offering.

  8. Show article details.

    BRIEF-Phasebio Reports Q4 And FY20 Financial Results

    Reuters – 8:11 AM ET 03/15/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS. * QTRLY LOSS PER SHARE $1.03. * Q4 EARNINGS PER SHARE VIEW $-0.71 -- REFINITIV IBES DATA. * CASH AND CASH EQUIVALENTS AT DEC 31, 2020 WERE $28.1 MILLION VERSUS $74.0 MILLION AT DEC 31, 2019 Source text for Eikon: Further company coverage:

  9. Show article details.

    PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

    Business Wire – 8:00 AM ET 03/15/2021

    Update on Phase 3 REVERSE-IT trial - enrollment ahead of schedule Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET Announced commercial supply agreement with BioVectra to support the development and commercialization of lead product candidate bentracimab Expanded pivotal Phase 3 REVERSE-IT trial of bentracimab into Cana...

  10. Show article details.

    BRIEF-PhaseBio Pharmaceuticals Says Co Obligated To Buy Minimum Of About $14 Mln Of Batches Of Product From BioVectra

    Reuters – 8:23 AM ET 03/11/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO PHARMACEUTICALS (PHAS) - PURSUANT TO MINIMUM ANNUAL COMMITMENTS, CO OBLIGATED TO BUY MINIMUM OF ABOUT $14 MILLION OF BATCHES OF PRODUCT IN YEARS 2022 THROUGH 2023 FROM BIOVECTRA. * PHASEBIO PHARMACEUTICALS (PHAS) - PURSUANT TO MINIMUM ANNUAL COMMITMENTS, CO OBLIGATED TO BUY ABOUT $37 MILLION OF BATCHES OF PRODUCT IN 2024 FROM BIOVECTRA.

  11. Show article details.

    BRIEF-PhaseBio Pharmaceuticals Says Entered Into Supply Agreement With BioVectra

    Reuters – 8:17 AM ET 03/11/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO PHARMACEUTICALS AND BIOVECTRA ENTER INTO SUPPLY AGREEMENT TO SUPPORT DEVELOPMENT AND COMMERCIALIZATION OF BENTRACIMAB. * PHASEBIO PHARMACEUTICALS (PHAS) - BIOVECTRA WILL PROVIDE ITS INTEGRATED CDMO SERVICES FOR MANUFACTURING OF ACTIVE PHARMACEUTICAL INGREDIENT OF BENTRACIMAB.

  12. Show article details.

    PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

    Business Wire – 8:00 AM ET 03/11/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization, today announced a commercial scale supply agreement for the production of bentracimab, PhaseBio’s lead product candidate currently...

  13. Show article details.

    PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

    Business Wire – 4:05 PM ET 02/26/2021

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences.

  14. Show article details.

     PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021

    Business Wire – 4:15 PM ET 02/24/2021

     Guest speakers Include Deepak Bhatt, MD, MPH and John Fanikos, RPh, MBA Presentations from PhaseBio Leadership Team PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host a virtual Investor and Analyst Day on March 15, 2021 from 12:00 p.m. to 2...

  15. Show article details.

    PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

    Business Wire – 8:00 AM ET 01/28/2021

    Cardiovascular disease remains a leading cause of mortality in both the European Union and globally, with antiplatelet therapy being a core treatment to prevent cardiovascular events The lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need Bentracimab has demonstrated immediate and susta...

  16. Show article details.

    BRIEF-PhaseBio Presents Data From Phase 1B/2A Trial Of Pemziviptadil To Treat Pulmonary Arterial Hypertension At Pulmonary Vascular Research Institute Virtual World Congress

    Reuters – 4:47 PM ET 01/27/2021

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO PRESENTS DATA FROM PHASE 1B/2A TRIAL OF PEMZIVIPTADIL FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION AT 15TH PULMONARY VASCULAR RESEARCH INSTITUTE VIRTUAL WORLD CONGRESS.

  17. Show article details.

    PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress

    Business Wire – 4:05 PM ET 01/27/2021

    New data for pemziviptadil support continued evaluation as a potential novel therapy of once-weekly VIP analogue for adults with pulmonary arterial hypertension; novel agent observed to be well tolerated, with no drug-related serious adverse events resulting in study drug discontinuation MALVERN, Pa. & SAN DIEGO---- PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company foc...

Page:

Today's and Upcoming Events

  • May
    11

    PHAS to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Mar
    15

    PHAS announced Q4 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.